Minnesota's smart step to ease access to COVID drug

A pioneering move to ease access to a powerful COVID-19 treatment will help protect Minnesotans against the severe illness this virus remains capable of causing.

It should also serve as an example to other states of the ongoing need to innovate at this stage of the pandemic.

More than two years after the pandemic began, there are still lives to be saved. Making it easier to get Paxlovid, a prescription drug close to 90% effective against hospitalization and death in those infected, as Minnesota did this week, is smart. It's commendable that the state is leading the way nationally.

On Wednesday, Gov. Tim Walz's office announced that five state-run community testing sites can now fill a prescription on the spot for Paxlovid.

Previously, these sites could test for COVID and provide a Paxlovid prescription for those eligible to use it. But getting the pills in hand required additional steps: finding a pharmacy stocking Paxlovid, then traveling there. Minnesota's new one-stop shopping approach will help ensure that the newly infected start the five-day treatment as soon as possible.

That timing is critical. While vaccines remain the most potent weapon against COVID, Paxlovid is an important addition to help those who become infected. But it must be taken within five days of symptom onset.

On-site Paxlovid prescriptions are now available at no cost at the state's "Test to Treat" locations in St. Paul-Midway, Moorhead, Brooklyn Park, Duluth and at the Minneapolis-St. Paul International Airport. The drug is limited to those 12 and older who are considered at high risk of becoming severely ill. Generally, risk factors include age or having underlying health conditions. For a complete list from the U.S. Centers for Disease Control (CDC), go to tinyurl.com/risk-factor-list.

Making it easier to fill a Paxlovid prescription will also help address the concerns raised by a recent CDC report. The June 24 report found that dispensing rates nationally for Paxlovid and another oral antiviral drug "were lowest in high-vulnerability zip codes," a term that often references neighborhoods faced with poverty and other challenges.

Authors called for additional efforts to "help to decrease barriers to oral antiviral access, particularly in communities with high social vulnerability." Filling Paxlovid prescriptions swiftly at the community test sites is a sensible response to the troubling disparities the CDC uncovered, though more solutions are needed.

Minnesota appears to be one of two states to fill antiviral drug prescriptions at community sites. Rhode Island claims to be the first to do so. New York City is taking a similar step.

This commonsense strategy stands in welcome contrast to inaction elsewhere or even worse, putting up barriers to prevent serious COVID illness. On Tuesday, Florida's surgeon general said his state had decided to block "county health departments from obtaining the newly FDA-approved COVID-19 vaccines for young children," the Miami Herald reported. This may have prevented "an estimated 30,000 disadvantaged kids from accessing the vaccines."

Florida Gov. Ron DeSantis, a Republican, has downplayed COVID's threat and derided prevention measures as "COVID theater."